SequelSEC

Rani Therapeutics Holdings, Inc. RANI

Pharmaceutical Preparations · CIK 0001856725 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$4.88M
Fiscal year ended 2026-06-30
Operating income
-$32.96M
Fiscal year ended 2026-06-30
Free cash flow
-$20.34M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$65.00MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float / revenue39.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.6×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
SBC / revenue722.5%88th
FCF margin-1151.4%22th
Revenue YoY growth58.9%77th
R&D / revenue1237.3%76th
Operating margin-2346.0%24th
Net margin-1817.1%25th
CapEx / revenue5.4%68th
Current ratio4.21x55th

Rani Therapeutics Holdings, Inc. (RANI) reported revenue of $4.88M and net income of -$30.14M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Rani Therapeutics Holdings, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Rani Therapeutics Holdings, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$4.88M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$32.96M
Net income-$30.14M
Research & development$18.31M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$19.53M
Selling & marketingUnavailable

Balance

Rani Therapeutics Holdings, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$4.87M
Total assets$60.84M
Current assets$56.52M
Total liabilities$12.86M
Current liabilities$10.64M
Total equity incl. NCI$47.98M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$2.04M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$1.05M

Cash flow

Rani Therapeutics Holdings, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$20.29M
Capital expenditures$47.00K
Investing cash flow-$47.98M
Financing cash flow$62.62M
Net change in cash-$5.65M
Stock-based compensation$9.09M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$722.00K

Derived

Rani Therapeutics Holdings, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$20.34M
Gross marginUnavailable
Operating margin-675.8%
FCF margin-417.0%
SBC / revenue186.4%
Current ratio5.31x
Revenue YoY growth306.4%
Net margin-618.0%
R&D / revenue375.4%
CapEx / revenue1.0%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RANI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.